Bharat Biotech Seeks DCGI's Nod To Conduct Nasal Covid Vaccine Trials, Say Sources

Hyderabad-based Bharat Biotech has applied to the DGCI to start Phase 1 and 2 trials of their nasal coronavirus vaccine.

Bharat Biotech has knocked on the Drugs Controller General of India's (DCGI) doors, seeking permission to conduct clinical trials of their intranasal vaccine for COVID-19.

Clinical trials of the 'BBV154' - a novel adenovirus vectored, intranasal vaccine for coronavirus -- will be conducted at various locations. The vaccine will be a single-dose one.

Nearly 70% Indians Hesitant to Take COVID-19 Vaccine
India is gearing up for the mass-vaccination drive and is about to begin within few days. However, about 69 percent Indians are still hesitant to take the Covid-19 shot.

‘Hyderabad-based Bharat Biotech has applied to the DGCI to start Phase 1 and 2 trials of their nasal coronavirus vaccine.’

The nasal vaccine is different from the two intramuscular vaccines which recently got approval, due to being non-invasive, needle-free, not requiring trained healthcare workers, eliminating needle-associated risks, and suitable for children and adults, having scalable manufacturing.

According to the firm, an intranasal vaccine stimulates a broad immune response at the site of infection, in the nasal mucosa, which is essential for blocking both infection and transmission of Covid-19.

The vaccine has demonstrated protective efficacy in mice and hamsters. Mice and hamsters immunised with its single dose conferred superior protection against SARS-CoV-2 challenge, "more so than one or two intramuscular immunisations of the same vaccine and dose".

Over 73,000 Get COVID-19 Vaccines In Beijing
In Beijing, over 73,000 people have received the COVID-19 vaccine shot in just two days after. The inoculation began on January 1 across 220 venues in Beijing and currently covers nine groups of people aged 18 to 59 in Beijing.

"Thus, intranasal immunisation of ChAd-SARS-CoV-2-S can create an immune response in the nose, which is the point of entry for the virus, thereby protecting against disease, infection and transmission," Bharat Biotech said in a statement.

On January 3, two intramuscular vaccines - Bharat Biotech's Covaxin and Oxford-AstraZeneca's Covishield manufactured by Serum Institute of India - were approved for restricted emergency use. Both are two-dose vaccines.

Bharat Biotech: Recruits 23,000 Volunteers for Phase 3 Trials
India's first indigenous COVID-19 vaccine developed by Bharat Biotech in collaboration with ICMR-NIV has recruited 23,000 volunteers for the phase 3 trials of Covaxin.

While the full efficacy of Covaxin is yet to be determined, it was given go-ahead by the DCGI citing 'public interest'. Covaxin is an indigenously developed vaccine by Bharat Biotech, in collaboration with the Indian Council of Medical Research (ICMR).

Source-IANS

Bharat Biotech Covaxin Not Approved: Experts
The data provided by Bharat Biotech for its coronavirus vaccine 'Covaxin' is not sufficient for emergency use and hence, has not been approved by the experts.